Why the study?
Recent unexpected basic science findings regarding the molecular pathomechanism of CPVT may provide deeper understanding to guide pharmacological treatments and precision medicine.
Answers are grounded in this paper and cite their sources.
Detailed understanding of the molecular pathomechanisms of specific RyR2 mutations in CPVT may lead to improved, tailored pharmacological treatments.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Niggli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: